MYX since the AGM has had a stella run and it’s nice to see its...

MYX since the AGM has had a stella run and it’s nice to see its previous forecast back in Feb of US$2.7m of EBITDA on average per month during FY16 from the acquisition of Doryx and brining in house distribution has been what the company has stated plus further growth of their other generic products.

MYX has totally transformed from a couple of years ago, to a Billion dollar company with further potential to grow its products and the countries they do business in.

Its been a positive transformation and Im glad they are diversifying their products because the Doryx 200mg tablet is a sizeable part of their total sales and profit with around 4,800 scrips per week whereas the 50mg represents around 600 scrips and growing.

It will be interesting when the Doryx 200mg exclusivity stops in April 2016 if this will have an impact on its sales and profit. However its encouraging the company is also focusing on the next generation products using doxycycline which could have significant upside. MYX haven’t updated their guidance or the board given much discussion on dividends rather deciding to reinvesting funds back into their R&D program.

The first 6 months of this fiscal year should be very promising and as a long term holder still happy with their progress going forward.

Good Luck to holders

Cheers Matsim